• PharmaLogic agreed to acquire Lantheus' contract development and manufacturing business and Springfield, New Jersey, manufacturing facility.
• The acquisition expands US radiopharmaceutical manufacturing capacity, creating a transatlantic platform for radioligand therapies through PharmaLogic's Agilera franchise.
• Agilera will manufacture lutetium Lu 177 dotatate under a long-term supply agreement included in the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: FL92623) on November 09, 2026, and is solely responsible for the information contained therein.